Category: Antibody Discovery

Bispecific Antibodies Enable Safer Cancer Therapy Through Tumor-Selective Targeting Strategies Introduction Many cancer therapies fail to achieve their full potential because the molecular targets driving tumor growth are also essential for normal tissue function. Blocking pathways such as Wnt, EGFR, or FGFR1 can effectively inhibit tumors but often causes severe toxicity in healthy organs. A …

Optimizing scFv Linker Design to Improve Antibody Stability and Binding Performance Introduction Single-chain variable fragments (scFv antibodies) are widely used in antibody engineering due to their compact size, efficient expression, and compatibility with applications such as bispecific antibodies, CAR-T cell therapies, and fusion proteins. An scFv consists of VH and VL antibody domains connected by …

Downstream Purification Strategies for High-Quality VHH Antibody Production Introduction VHH antibodies, also known as nanobodies, are the smallest antibody fragments (~12–15 kDa) and have gained increasing attention due to their compact size, high stability, and ability to access unique epitopes. Following VHH discovery and VHH phage display screening, successful candidates require optimized expression and purification …

Somatic Mutations in Microglia Reveal a New Mechanism Driving Alzheimer’s Disease Progression Introduction Alzheimer’s disease (AD) is a complex neurodegenerative disorder traditionally associated with β-amyloid accumulation, Tau pathology, chronic inflammation, and neuronal loss. While microglia play a central role in regulating brain immune responses, the genetic mechanisms controlling their dysfunction remain poorly understood. A recent …

CAR-A for Alzheimer’s: A Breakthrough Neuro-Immunotherapy Using Engineered Astrocytes Introduction Alzheimer’s disease (AD) remains a major challenge, with current anti-Aβ monoclonal antibodies requiring high doses, repeated administration, and carrying risks like ARIA. A pioneering study in Science introduces CAR-A therapy—a next-generation neuro-immunotherapy that engineers astrocytes into super-phagocytes via Chimeric Antigen Receptors. This self-sustaining, one-time intervention …

Phage vs. Yeast Display: Why Eukaryotic Expression Wins for Antibody Developability In therapeutic antibody discovery, platform choice dictates downstream success. While phage display remains prized for its library size, yeast surface display—powered by eukaryotic expression—is rapidly becoming the industry standard for generating developable, manufacturable candidates. By leveraging Saccharomyces cerevisiae’s secretory machinery, yeast display ensures that selected …

The advent of CRISPR-Cas systems, particularly CRISPR/Cas9, has revolutionized the field of genetic engineering, offering unprecedented precision in editing the genomes of various organisms. This groundbreaking technology has significantly impacted antibody engineering, enabling the generation of custom antibodies and the precise modification of antibody genes. This article explores the role of CRISPR/Cas9 in antibody engineering, …

Yeast surface display has emerged as a powerful and versatile technology for antibody discovery and protein engineering, playing a critical role in therapeutic development. By leveraging the eukaryotic machinery of yeast, this platform ensures proper protein folding and display, enabling the isolation of high-affinity binders through robust library screening. Technology Overview (i) Display Mechanism The …

Protein-protein interactions (PPIs) govern cellular communication and are prime targets for therapeutic intervention. Peptide library screening has emerged as a powerful, high-throughput strategy to dissect these interactions with precision. By systematically displaying thousands of peptide sequences, researchers can map binding epitopes, identify lead compounds, and optimize candidates efficiently. This article outlines the core strategies, technical …